注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
XTL Biopharmaceuticals Ltd是一家生物製藥公司,致力於收購和開髮用於治療自身免疫性疾病的藥物。該公司在研對象包括hCDR1系統性紅斑狼瘡和重組人促紅細胞生成素(rHuEPO)多發性骨髓瘤。其hCDR1是系統性紅斑狼瘡(SLE)和乾燥綜合徵(SS)的潛在治療方法。 hCDR1是皮下施用的肽(短蛋白),並且充當疾病特異性治療以修飾SLE相關的自身免疫過程。 rHuEPO已知貧血藥物,可延長患者的生存期,用於治療多發性骨髓瘤血癌。其促紅細胞生成素(EPO)是主要由腎臟產生的糖蛋白激素。促紅細胞生成素通過與紅細胞祖細胞表面的受體結合,促進其增殖和分化,並維持其活力,從而促進紅細胞生成。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Daniel J. Wallace | - | - | Member of Clinical Advisory Board |
Osnat Hillel Fain | 55 | 2015 | Independent Non-Executive & External Director |
Murray Urowitz | - | - | Member of Clinical Advisory Board |
Robert I. Fox | - | 2017 | Member of Clinical Advisory Board |
Lee S. Simon | 70 | - | Member of Clinical Advisory Board |
Simon Bowman | - | 2017 | Member of Clinical Advisory Board |
David Isenberg | - | 2015 | Member of Clinical Advisory Board |
Jonathan Schapiro | 61 | 2014 | Non-Executive Director |
Shlomo Spokone Shalev | 59 | 2014 | CEO & Director |
Doron Turgeman | 53 | 2014 | Non-Executive Chairman of the Board |
Alexander Rabinovich | 51 | 2017 | Non-Executive Director |
Dobroslav Melamed | 46 | 2014 | Independent Non-Executive Director |
Iris Shapira Yalon | 56 | 2020 | Independent Non-Executive & External Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核